Premium
Review article: vitamin D and inflammatory bowel disease – established concepts and future directions
Author(s) -
Garg M.,
Lubel J. S.,
Sparrow M. P.,
Holt S. G.,
Gibson P. R.
Publication year - 2012
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2012.05181.x
Subject(s) - medicine , vitamin d and neurology , calcitriol receptor , immune system , paracrine signalling , inflammatory bowel disease , disease , autocrine signalling , bone health , bioinformatics , immunology , receptor , intensive care medicine , osteoporosis , bone mineral , biology
Summary Background Understanding of the role of vitamin D in health and disease has increased markedly in the past decade, with its involvement extending well beyond traditional roles in calcium and phosphate homeostasis and musculoskeletal health. This conceptual expansion has been underpinned by identification and exploration of components of this axis including vitamin D ‐binding protein, key enzymes and receptors in multiple cell types, and a greater recognition of nonclassical autocrine and paracrine effects. Its influence in IBD remains uncertain. Aim To review the role of vitamin D in bone health, immune regulation and cancer prevention in IBD , and to outline practical issues and limitations of its use. Methods An extensive online literature review including PubMed and Medline. Results In patients with IBD , the vitamin D axis provides an important and often underutilised pathway to preserving bone health. Furthermore, an exciting body of clinical and basic science research demonstrates that these pathways may have an integral part to play in regulation of the immune response in IBD , through effects on the intestinal barrier, antigen presenting cells and adaptive T cells. The possibility of chemoprevention requires further study. The optimal target level of 25‐hydroxy vitamin D in patients with IBD is currently uncertain, as is the best therapeutic modality. Conclusions Study of vitamin D pathways may result in the development of relatively inexpensive therapeutic options to optimise patient outcomes. Further prospective clinical research is required to address efficacy and long‐term safety.